Published on 11 July 2022
Description:
New PharmaTimes is about progress – it’s about going beyond perceived limitations and defying outdated cultures. It’s about flexible pharma environments, the future of biosimilars, the emergence of DNA synthesis, gene therapy advancement and sustainability in medicine manufacturing. It’s also about a parent’s very personal account of disease management and how a single experience can change the world.
Categories:
PharmaTimes28 articles from this collection:
Cover
2 - PharmaTimes Marketer of the Year
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020.
4-5 - Contents
6 - Treatments
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
7 - Industry
8 - Collaboration
9 - Conditions
10-11 - COVER STORY: Tomorrow's World
12-13 - NHS: A quiet revolution?
14-15 - INDUSTRY: Our imagination
16-17 - PHARMATIMES AWARDS
18-19 - PARTICIPATION: Be patient
20-21 - FLYPHARMA: Perfectly logical explanation
22-23 - BIOSIMILARS: Stark similarities
24 - FLYPHARMA
25 - GENE THERAPY: Whole new world
26-27 - DIVERSITY: Vision for diversity
28-29 - THERAPIES: Synth revival
30 - AI: Changing channels
31 - INDUSTRY: Market forces
32-33 - PATIENT EXPERIENCE: Group Therapy
34-35 - Your moves
36 - Samedan LTD
37 - SUSTAINABILITY: Chemical reaction
38 - INNOVATION: New direction
39 - Pharmatimes CROY
40 - Dr Wolff's Vagisan
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.